Maaike P G Vreeswijk
Overview
Explore the profile of Maaike P G Vreeswijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Wijk L, Nilas A, Vrieling H, Vreeswijk M
Expert Rev Mol Diagn
. 2021 Dec;
22(2):185-199.
PMID: 34913794
Introduction: Carcinomas with defects in the homologous recombination (HR) pathway are sensitive to PARP inhibitors (PARPi). A robust method to identify HR-deficient (HRD) carcinomas is therefore of utmost clinical importance....
12.
Boonen R, Wiegant W, Celosse N, Vroling B, Heijl S, Kote-Jarai Z, et al.
Cancer Res
. 2021 Dec;
82(4):615-631.
PMID: 34903604
Significance: Quantitative assessment of the functional consequences of CHEK2 variants of uncertain significance identifies damaging variants associated with increased cancer risk, which may aid in the clinical management of patients...
13.
van Wijk L, Kramer C, Vermeulen S, Ter Haar N, de Jonge M, Kroep J, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34203855
PARP inhibitor (PARPi) sensitivity is related to tumor-specific defects in homologous recombination (HR). Therefore, there is great clinical interest in tests that can rapidly and reliably identify HR deficiency (HRD)....
14.
Bueno-Martinez E, Sanoguera-Miralles L, Valenzuela-Palomo A, Lorca V, Gomez-Sanz A, Carvalho S, et al.
Cancers (Basel)
. 2021 Jul;
13(11).
PMID: 34200360
loss-of-function variants increase lifetime risk of breast and ovarian cancer. Splicing disruption is a frequent pathogenic mechanism associated with variants in susceptibility genes. Herein, we have assessed the splicing and...
15.
Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, et al.
N Engl J Med
. 2021 Jan;
384(5):428-439.
PMID: 33471991
Background: Genetic testing for breast cancer susceptibility is widely used, but for many genes, evidence of an association with breast cancer is weak, underlying risk estimates are imprecise, and reliable...
16.
Sanoguera-Miralles L, Valenzuela-Palomo A, Bueno-Martinez E, Llovet P, Diez-Gomez B, Caloca M, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33333735
Hereditary breast and/or ovarian cancer is a highly heterogeneous disease with more than 10 known disease-associated genes. In the framework of the BRIDGES project (Breast Cancer Risk after Diagnostic Gene...
17.
Boonen R, Vreeswijk M, van Attikum H
Front Mol Biosci
. 2020 Nov;
7:169.
PMID: 33195396
In recent years it has become clear that pathogenic variants in are associated with a high risk for breast, ovarian and pancreatic cancer. However, the clinical relevance of variants of...
18.
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
van Wijk L, Vermeulen S, Meijers M, van Diest M, Ter Haar N, de Jonge M, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33003546
Recent studies have shown that the efficacy of PARP inhibitors in epithelial ovarian carcinoma (EOC) is related to tumor-specific defects in homologous recombination (HR) and extends beyond deficient EOC. A...
19.
Mesman R, Calleja F, de la Hoya M, Devilee P, van Asperen C, Vrieling H, et al.
Genet Med
. 2020 Jun;
22(8):1427-1428.
PMID: 32576986
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
20.
de Groot S, Lugtenberg R, Cohen D, Welters M, Ehsan I, Vreeswijk M, et al.
Nat Commun
. 2020 Jun;
11(1):3083.
PMID: 32576828
Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI...